Please use this identifier to cite or link to this item:
http://ir.mu.ac.ke:8080/jspui/handle/123456789/3266
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Manji, Imran | - |
dc.contributor.author | Pastakia, Sonak D | - |
dc.date.accessioned | 2020-08-03T07:50:19Z | - |
dc.date.available | 2020-08-03T07:50:19Z | - |
dc.date.issued | 2019-02 | - |
dc.identifier.uri | https://doi.org/10.1016/S2214-109X(19)30049-X | - |
dc.identifier.uri | http://ir.mu.ac.ke:8080/jspui/handle/123456789/3266 | - |
dc.description.abstract | Pharmaceutical companies are often maligned for many of the limitations in medication access in low-income and middle-income countries. Furthermore, many of their efforts to support health-care delivery in these settings are viewed solely as efforts to improve public relations and are not typically subjected to the in-depth peer review that most health-care interventions receive before dissemination to the public. In The Lancet Global Health, Peter Rockers and colleagues1 present a necessary and timely evaluation of an industry-led initiative to improve medicine access, which helps to change this narrative and provides many lessons to others in the pharmaceutical industry who are embarking on similar access programmes. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Lancet Global health | en_US |
dc.subject | Medication access | en_US |
dc.subject | Non-communicable disease | en_US |
dc.title | Novartis Access: a small step towards increased access for non-communicable disease care | en_US |
dc.type | Article | en_US |
Appears in Collections: | School of Medicine |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.